Life Sciences

  • April 21, 2026

    Novo Nordisk Unit Can't Slip Former Exec's Sex, Age Bias Suit

    A Novo Nordisk unit must face a former finance director's lawsuit claiming she was fired because she was an older woman who complained about a male co-worker's behavior, with a North Carolina federal judge ruling her allegations were detailed enough to stay in court.

  • April 21, 2026

    Purdue Pharma Sentencing Punted For In-Person Attendance

    A New Jersey federal judge delayed Oxycontin maker Purdue Pharma's criminal sentencing by a week, saying rescheduling would give an in-person attendance option to hundreds of observers who tuned in virtually Tuesday.

  • April 21, 2026

    Ga. Justices Confront Fed, State Power Divide In Bio-Lab Suit

    Georgia's highest court seemed to struggle Tuesday with whether it had the authority to tell a federal judge if residents suing chlorine products company Bio-Lab Inc. over the aftermath of a 2024 fire could ask for medical monitoring as part of their class action.

  • April 21, 2026

    Philly Zantac Judge Again Declines To Recuse From Cases

    A Philadelphia judge overseeing the Zantac mass tort litigation against GlaxoSmithKline has once again denied a motion to recuse himself from the cases, claiming that his wife's affiliation with a firm representing a defendant in the litigation did not present a conflict that required him to step away.

  • April 20, 2026

    Armistice Head Testifies He Accidentally Deleted Texts

    Armistice Capital's founder, who is facing investor claims that the hedge fund dumped its artificially inflated shares in pharmaceutical company Vaxart for $250 million, told a California federal jury Monday that during a physical therapy session held over Skype, he accidentally deleted key text messages with another Armistice executive.

  • April 20, 2026

    Beasley Allen Pro Hac Vice Revoked In Philly J&J Talc Cases

    A Pennsylvania state court has booted Beasley Allen Law Firm attorneys from representing consumers in nine cases that link Johnson & Johnson's talcum powder to ovarian cancer, saying their pro hac vice admission was inappropriate given the firm's dealings with an attorney who previously represented the company.

  • April 20, 2026

    Quinn Emanuel May Face More Sanctions In Guardant Fight

    Guardant Health Inc. urged a California federal judge on Monday to make Quinn Emanuel pay nearly $1.3 million on top of $3 million in sanctions already imposed over misrepresentations lawyers made representing its rival Natera Inc., prompting the judge to criticize Quinn Emanuel lawyers for making distinctions so fine they veer into misrepresentation.

  • April 20, 2026

    Philip Morris Unfairly Gains From Label Ruling, 11th Circ. Told

    Philip Morris cannot be the only company allowed to not follow a rule requiring cigarette makers to add graphic warnings to their labels, R.J. Reynolds and a coalition of tobacco businesses have told the Eleventh Circuit, suggesting that consumers might assume its cigarettes are safer than theirs.

  • April 20, 2026

    ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says

    Biotechnology company ImmunityBio Inc.'s stock slipped by 21% after misleading statements on a podcast by the company's founder about its lead cancer drug prompted the issuance of a warning letter from the U.S. Food and Drug Administration, according to a shareholder derivative suit in California federal court.

  • April 20, 2026

    SEC Says Adviser Traded On Firm Clients' Confidential Info

    The U.S. Securities and Exchange Commission sued an ex-investment advisory firm associate in Manhattan federal court on Monday, accusing him of using a close relative's brokerage account to trade ahead of market-moving announcements by three biopharmaceutical and biotechnology companies that his firm was researching.

  • April 20, 2026

    PFAS Plaintiffs Say Midcase Appeal Would 'Derail' Litigation

    Georgia residents accusing carpet and chemicals manufacturers of contaminating their properties with forever chemicals urged a state court to reject Shaw Industries' bid to appeal the recent nondismissal of their claims, arguing the request is the carpet company's latest "attempt to derail this litigation."

  • April 20, 2026

    PBMs Fail To Freeze Discovery In Mich.'s Drug-Pricing Case

    A pending motion to dismiss the Michigan attorney general's drug-pricing case against multiple pharmacy benefit managers does not preclude the PBMs from handing over agreements between PBMs and pharmacies to the state, a federal judge said in a motion hearing Monday.

  • April 20, 2026

    She Has A Point: Fish & Richardson's Nitika Gupta Fiorella

    Fish & Richardson PC principal Nitika Gupta Fiorella is "a no-stone-unturned, always super prepared" lawyer who "epitomizes professionalism and respect," according to Finnegan Henderson Farabow Garrett & Dunner LLP partner Cora Holt.

  • April 20, 2026

    Doctors Fueled Man's Fatal Opioid Addiction, Philly Jury Told

    Counsel for the family of a man who died of an opioid overdose at age 26 told a Philadelphia jury that his doctors were responsible for pushing treatment plans that allowed him to develop an opioid addiction, leading to his untimely death, pointing to both physicians being paid speakers for the pharmaceutical companies whose medications they prescribed.

  • April 20, 2026

    Justices Mull Limits On Federal Review Of State Cases

    The U.S. Supreme Court on Monday wrestled with the potential impact of reining in — or even scrapping altogether — a 100-year-old doctrine that curbs litigants' ability to go to federal court to try to overturn a state court loss.

  • April 20, 2026

    House Panel Probes Reports Of Missing, Killed Scientists

    Two Republican U.S. congressmen announced a probe Monday into reports of about a dozen scientists or government employees with ties to American nuclear and space programs who were killed or reported missing, penning letters seeking information from NASA, the Department of Energy, the FBI and the Defense Department.

  • April 20, 2026

    GSK, Moderna Both Ordered To Provide More Info In Vax Fight

    A special master overseeing discovery disputes in GlaxoSmithKline's infringement suits over Moderna's COVID-19 and related respiratory syncytial virus vaccines ordered both companies to furnish information to each other, including financial data and licenses, according to an opinion unsealed Monday.

  • April 20, 2026

    Trump Orders Agencies To Fast-Track Psychedelic Therapies

    President Donald Trump on Saturday announced that his administration would instruct federal agencies to accelerate investigations into new therapies derived from psychedelic drugs and streamline patients' access to the treatments.

  • April 20, 2026

    White & Case Partner Moves To A&O Shearman In DC

    Allen Overy Shearman Sterling has hired a career White & Case LLP partner in Washington, D.C., who had spent the past 13 years there working with antitrust and other matters, the firm announced Monday.

  • April 20, 2026

    Kirkland, Goodwin Guide Lilly's Potential $7B Kelonia Buy

    Kirkland & Ellis LLP-advised pharmaceutical giant Eli Lilly & Co. on Monday announced plans to acquire clinical-stage biotechnology company Kelonia Therapeutics, led by Goodwin Procter LLP, in a deal worth up to $7 billion.

  • April 20, 2026

    High Court Won't Hear 3rd Circ. J&J Class Cert. Appeal

    The U.S. Supreme Court on Monday said it won't review a class certification challenge in a securities class action over Johnson & Johnson's cancer-related talc products in the latest development in a closely watched dispute over how courts evaluate class certification in shareholder suits.

  • April 20, 2026

    Justices Won't Consider IP Theft Allegations Against Akin

    The U.S. Supreme Court on Monday rejected a former Cornell University graduate student's petition trying to revive his malpractice suit against Akin Gump Strauss Hauer & Feld LLP stemming from patent litigation against Illumina Inc. over DNA sequencing intellectual property.

  • April 17, 2026

    Bayer Loses Bid To Block J&J's Cancer Drug Survival Claims

    A Manhattan federal judge Friday refused to block Johnson & Johnson from advertising its prostate cancer drug as having a lower risk of death compared with Bayer's medication, saying Bayer has not shown it is likely to succeed on its claims that its rival's advertising campaign is false or misleading.

  • April 17, 2026

    ITC Clears Apple's Redesigned Apple Watch For Import

    The U.S. International Trade Commission on Friday signed off on an administrative law judge's finding that Apple has sufficiently redesigned its smartwatch so it doesn't infringe Masimo Corp.'s patents and is therefore not bound by a 2023 import ban.

  • April 17, 2026

    Missed Deadline Fatal To Patient's Stapler Suit, 4th Circ. Says

    The Fourth Circuit ruled Friday that a surgery patient's missed expert disclosure deadline rightfully ended his case seeking to hold Johnson & Johnson subsidiary Ethicon Endo-Surgery LLC liable for allegedly faulty staples used in his procedure.

Expert Analysis

  • Utah's AI Prescription Renewal Pilot Could Inform Policy

    Author Photo

    Utah recently became the first state to approve an artificial intelligence system for autonomously renewing certain prescription medicines, providing a test case for how regulators may be able to draw boundaries between administrative automation and medical judgment, say Jashaswi Ghosh at Holon Law Partners and Bryant Godfrey at Foley Hoag.

  • Ramped Up Psychedelic Production Carries Opportunity, Risk

    Author Photo

    Kimberly Chew at Husch Blackwell discusses the key legal implications of the U.S. Drug Enforcement Administration's recent dramatic increases in the production quotas for a range of psychedelic substances, offering guidance on compliance, risk management and strategic opportunities for practitioners navigating this rapidly evolving landscape.

  • Series

    Teaching Logic Makes Me A Better Lawyer

    Author Photo

    Teaching middle and high school students the skills to untangle complicated arguments and identify faulty reasoning has made me reacquaint myself with the defined structure of thought, reminding me why logic should remain foundational in the practice of law, says Tom Barrow at Woods Rogers.

  • New Biotech Nat'l Security Controls May Have Blunted Impact

    Author Photo

    While the newly enacted federal prohibition against contracting with certain biotechnology providers associated with countries of concern may have consequences on U.S. companies' ability to develop drugs, the restrictions may prove to be less problematic for the industry than the significant publicity around their passage would suggest, say attorneys at Wilson Sonsini.

  • From IPR To EPR: The Rapid Rise Of Ex Parte Reexamination

    Author Photo

    With the current administration's dramatic shifts in policy rendering inter partes reviews essentially unavailable for the majority of patents being asserted in litigation, IPR filing rates have plunged, and ex parte reexamination requests have surged to the average rate of IPR petitions in 2024, say attorneys at McKool Smith.

  • Series

    Law School's Missed Lessons: Practicing Resilience

    Author Photo

    Resilience is a skill acquired through daily practices that focus on learning from missteps, recovering quickly without internalizing defeat and moving forward with intention, says Nicholas Meza at Quarles & Brady.

  • Takeaways From The DOJ Fraud Section's 2025 Year In Review

    Author Photo

    Former acting Principal Deputy Chief Sean Tonolli of the U.S. Department of Justice's Fraud Section, now at Cahill Gordon, analyzes key findings from the section’s annual report — including the changes implemented to adapt to the new administration’s priorities — and lays out what to watch for this year.

  • Upshot Of 'Skinny Label' Case May Go Beyond Pharma

    Author Photo

    The U.S. Supreme Court's pending review of Hikma v. Amarin, over a drugmaker's "skinny label," carries implications for both generics and brand-name pharmaceutical manufacturers, and could shed light on how inducement doctrine should operate in other regulated industries where products have substantial lawful uses, says Jason Shull at Banner Witcoff.

  • Assessing Factors Behind Biosimilar Uptake And Competition

    Author Photo

    As biosimilar uptake remains uneven and questions linger over whether the Biologics Price Competition and Innovation Act can deliver robust competition between biologics and biosimilars, a case study of Humira and its biosimilars illustrates how many factors, including payor reimbursement and formulary strategy, collectively shape competitive dynamics, say analysts at Analysis Group.

  • Traditional FCA Enforcement Surges Amid Shifting Priorities

    Author Photo

    The U.S. Department of Justice’s January report on False Claims Act enforcement in fiscal year 2025 reveals that while the administration signaled its intent to expand FCA enforcement into new areas such as tariffs, for now the greatest exposure remains in traditional areas like healthcare — in which the risk is growing, say attorneys at Debevoise.

  • NYC Bar Opinion Warns Attys On Use Of AI Recording Tools

    Author Photo

    Attorneys who use artificial intelligence tools to record, transcribe and summarize conversations with clients should heed the New York City Bar Association’s recent opinion addressing the legal and ethical risks posed by such tools, and follow several best practices to avoid violating the Rules of Professional Conduct, say attorneys at Smith Gambrell.

  • Series

    The Biz Court Digest: Dispatches From Utah's Newest Court

    Author Photo

    While a robust body of law hasn't yet developed since the Utah Business and Chancery Court's founding in October 2024, the number of cases filed there has recently picked up, and its existence illustrates Utah's desire to be top of mind for businesses across the country, says Evan Strassberg at Michael Best.

  • Checking In On Biologics-Related Patent Review Trends

    Author Photo

    Comprehensive analysis of Patent Trial and Appeal Board data since the PTAB's creation indicates that while inter partes review and post-grant review are potent weapons for challenging biologics-related patents, recent policy changes may reduce their effectiveness, say attorneys at Steptoe.

  • 4 Quick Emotional Resets For Lawyers With Conflict Fatigue

    Author Photo

    Though the emotional wear and tear of legal work can trap attorneys in conflict fatigue — leaving them unable to shake off tense interactions or return to a calm baseline — simple therapeutic techniques for resetting the nervous system can help break the cycle, says Chantel Cohen at CWC Coaching & Therapy.

  • Rescheduling Cannabis Marks New Tax Era For Operators

    Author Photo

    As the attorney general takes steps to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, operators and advisers should prepare by considering the significant changes this will bring from tax, state, industry and market perspectives, says Michael Harlow at CohnReznick.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.